Approximately one half of patients develop ascites within 10 years of diagnosis of compensated cirrhosis. It is a poor prognostic indicator, with only 50% surviving beyond two years. Mortality worsens significantly to 20% to 50% at one year if the ascites becomes refractory to medical therapy.
View Article and Find Full Text PDFJ Coll Physicians Surg Pak
January 2016
J Coll Physicians Surg Pak
October 2008
Objective: To determine the efficacy of 12 weeks therapy with conventional interferon and ribavirin in chronic hepatitis C genotype 2 and 3 naive patients.
Study Design: A randomized clinical trial.
Place And Duration Of Study: Postgraduate Medical Institute, Lady Reading Hospital, Peshawar, from January 2005 to October 2006.